How should dengue myocarditis be diagnosed and managed?

Dengue Myocarditis: Diagnosis and Management

Dengue myocarditis should be diagnosed using cardiac troponin, ECG, and echocardiography in any dengue patient with cardiac symptoms (chest pain, dyspnea, palpitations) or hemodynamic instability, with cardiac magnetic resonance (CMR) imaging for confirmation in stable patients, followed by supportive care including guideline-directed heart failure therapy and cardiology consultation.

Diagnostic Approach

When to Suspect Dengue Myocarditis

Maintain high clinical suspicion in dengue patients presenting with:

• Cardiac symptoms: chest pain, dyspnea, palpitations, syncope 1
• Hemodynamic instability: unexplained shock, fluid overload 2
• Arrhythmias: supraventricular tachycardia (including as initial presentation), ventricular arrhythmias, or conduction abnormalities 3
• Bleeding manifestations with respiratory distress 2

The prevalence is substantial at 12.4-21% among hospitalized dengue patients, with higher rates in Asia (15.2%) versus Latin America (3.6%) 4, 5. This is far more common than previously recognized and carries significant mortality risk.

Initial Diagnostic Testing

For all suspected cases, immediately obtain:

1. Cardiac troponin (preferably high-sensitivity assay) - elevated in myocarditis 6, 1
2. 12-lead ECG - may show ST-segment elevation, T-wave changes, AV blocks, bundle branch blocks, arrhythmias, or conduction delays 1
3. Echocardiography - assess for regional/global wall motion abnormalities, ventricular dysfunction, pericardial effusion 6, 1
4. NT-proBNP - elevated in myocardial involvement 2

Confirmatory Testing

Cardiac MRI (CMR) is recommended in hemodynamically stable patients with suspected myocarditis 6, 7. CMR provides superior tissue characterization showing:

• Increased T2 signal (edema/inflammation)
• Late gadolinium enhancement (LGE) in non-ischemic pattern
• Increased native T1 mapping 1

Important caveat: Endomyocardial biopsy is rarely needed unless considering giant cell myocarditis or when results would change management decisions regarding mechanical support or transplantation 7.

Management Strategy

Immediate Actions

All patients with confirmed or suspected dengue myocarditis require:

1. Cardiology consultation - mandatory for rising troponin and/or ECG/echo abnormalities 6

2. Hospitalization - ideally at an advanced heart failure center for mild-moderate cases; fulminant cases require centers with mechanical circulatory support expertise 6, 7

3. Hemodynamic monitoring - dengue myocarditis patients are at high risk for cardiogenic shock requiring mechanical support 8

Medical Therapy

Supportive care is the cornerstone as there is no specific antiviral treatment for dengue:

• Guideline-directed heart failure therapy: ACE inhibitors/ARBs, beta-blockers, diuretics as clinically appropriate 6, 7
• Fluid management: Careful balance required - dengue patients need adequate hydration but myocarditis patients are prone to fluid overload 2
• Arrhythmia management: Rate/rhythm control per standard guidelines (e.g., diltiazem for SVT) 3

Immunosuppression considerations:

• Not routinely recommended for viral myocarditis 7
• May consider IV corticosteroids only in fulminant cases with hemodynamic compromise, severe myocardial infiltrates on biopsy, or refractory shock 6, 7
• Balance infection risk carefully as dengue is an active viral infection

Advanced Support

For fulminant dengue myocarditis with refractory cardiogenic shock:

• Venoarterial ECMO (VA-ECMO) has been successfully used, though mortality remains significant (50% in reported series) 8
• Early transfer to ECMO-capable center is critical
• Despite severity, prognosis for cardiac recovery is favorable in survivors 9, 8

Clinical Outcomes and Prognosis

Key prognostic data:

• Severity: 34% of dengue myocarditis cases develop severe disease 4
• Mortality: 26.4% overall mortality rate 4
• Risk stratification: Myocarditis increases risk of severe dengue (RR 2.44) and mortality (RR 19.41) compared to dengue without myocarditis 4
• Recovery: Survivors typically achieve full cardiac function recovery with appropriate support 9

Hospital course expectations:

• Longer hospitalization (7 vs. 4.8 days) compared to dengue without myocarditis 2
• Fluid overload complications are common (69% of myocarditis cases) 2

Activity Restriction

Exercise abstinence for 3-6 months following clinical myocarditis 6. Before return to activity, ensure:

• Resolution of cardiopulmonary symptoms
• Normalization of cardiac biomarkers
• Normal LV systolic function on imaging
• No spontaneous or inducible arrhythmias on monitoring/stress testing

Critical Pitfalls to Avoid

1. Don't dismiss cardiac symptoms in dengue patients - myocarditis prevalence is 12-21%, not rare 4, 5

2. Don't delay mechanical support in fulminant cases - early ECMO can be lifesaving despite high mortality 8

3. Don't routinely use immunosuppression - reserve for fulminant cases only, as dengue is an active viral infection 7

4. Don't overlook arrhythmias as presenting feature - SVT can be the initial manifestation even with normal echocardiography 3

5. Don't assume normal echo excludes myocarditis - CMR is more sensitive for detecting myocardial inflammation 1

6. Monitor for reinfection risk - secondary dengue infections with different serotypes can trigger more severe myocarditis 9